Full-Time

Director Clinical Sciences

Oncology

Updated on 8/9/2026

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Compensation Overview

$183.8k - $330.3k/yr

+ Annual discretionary bonus + Other incentive compensation + Equity award

No H1B Sponsorship

Cambridge, MA, USA + 1 more

More locations: Princeton, NJ, USA

Hybrid

Expected to work in-office 70% of the time, with flexibility to work from home up to 30%.

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Moderna

See people who can refer or advise you

Requirements
  • A PhD, Doctor of Pharmacy, Master's degree, or advanced nursing degree with significant scientific and clinical oncology knowledge, pharmaceutical or biotechnology company experience, and comprehensive knowledge of drug development.
  • A minimum of 10 years of clinical development experience within a pharmaceutical or biotechnology company.
  • Significant experience with clinical study design and protocol development.
  • Significant experience ensuring data integrity, data analysis, and data presentation.
  • Ability to contribute to early- and late-stage clinical development programs and collaborate closely with Drug Discovery, Translational Medicine, Regulatory Affairs, Biostatistics, Medical Affairs, and Commercial.
  • Ability to work successfully in a team environment and matrix environment.
  • Excellent written communication, oral communication, and presentation skills.
  • Ability to travel up to 15% to work with study sites and attend national and international scientific congresses.
Responsibilities
  • Support Oncology Therapeutic programs and the Clinical Development Lead in directing, executing, and evaluating Phase 1–3 clinical studies.
  • Ensure comprehensive clinical-study data quality to support internal governance decisions and regulatory submissions.
  • Contribute to regulatory and clinical program strategy, clinical trial design, and clinical study execution.
  • Author and review clinical study documents, including clinical protocols, informed consent documents, Development Safety Update Reports, and clinical components of Investigator Brochures, Investigational New Drug applications, and marketing applications, in compliance with regulatory standards.
  • Collaborate with the Clinical Development Lead to oversee clinical studies and lead studies with oversight when assigned.
  • Provide clinical study leadership, review and interpret clinical data, and ensure timely execution of deliverables with internal and external partners.
  • Coordinate clinical data review and analysis, including review of case report forms, data listings, medical coding, and patient profiles, to verify clinical data properly and completely.
  • Support management of study sites and ensure treatment-discontinuation and other safety decisions align with the protocol.
  • Participate in start-up and execution of global clinical studies to ensure on-schedule site activation and subject enrollment.
  • Design and implement clinical study parameters to minimize operational risk and improve study-site performance and efficiency.
  • Contribute to inspection-readiness activities supporting audits and regulatory inspections related to clinical-trial conduct.
  • Develop strategy and drive messaging and associated content for Investigator Meetings, investigator engagement, and Advisory Board meetings.
  • Train and educate junior Clinical Science personnel.
  • Support evolution of the clinical science role, process updates, and Development workstreams related to the clinical-trial delivery operating model.

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • mFLUSIVA approval opens a 2026 respiratory season revenue stream in adults 50 and older.
  • CEPI-funded Bundibugyo Ebola trial began August 2026, expanding Moderna's global health optionality.
  • Management guides 2026 revenue growth up to 10% and year-end cash of $4.7-$5.2 billion.

What critics are saying

  • Norovirus vaccine mRNA-1403 missed early-success criteria in July 2026, delaying a key launch.
  • Moderna paid $950 million in July 2026, plus $1.3 billion contingent on appeal.
  • Revenue stayed $145 million in Q2 2026, exposing dependence on uncertain vaccine launches.

What makes Moderna unique

  • mRNA-1010 won FDA approval August 5, 2026, Moderna's first seasonal flu mRNA vaccine.
  • Merck collaboration delivered intismeran melanoma data: 49% recurrence-or-death reduction at five years.
  • Moderna keeps a broad mRNA platform across vaccines, oncology, rare disease, and biodefense.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
CTV News
Aug 4th, 2026
Moderna begins first human trial of Bundibugyo Ebola vaccine.

Moderna begins first human trial of Bundibugyo Ebola vaccine. Published: August 04, 2026 at 2:10PM EDT Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine. Health Canada has cleared an early-stage study and the first volunteers have already received the shot, called mRNA-1469, acording to the vaccine maker. The experimental shot uses the same mRNA technology behind Moderna's COVID-19 vaccine. The trial, which will run at three sites in Canada, aims to enroll about 80 healthy adults to check if the vaccine is safe and triggers an immune response. The work is part of an expanded partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI, which has pledged up to US$50 million to help fund the vaccine's early testing and manufacturing. The Bundibugyo strain is driving an outbreak in Democratic Republic of Congo that has become the world's second-largest Ebola outbreak on record, with 3,748 confirmed cases and 1,657 confirmed deaths reported as of August 1, according to the U.S. Centers for Disease Control and Prevention data. The cases are increasing faster than during the 2014-2016 West Africa Ebola epidemic, which was the largest on record, said CEPI chief executive Richard Hatchett. The World Health Organization and Africa CDC have both declared the current outbreak a public health emergency. If the vaccine is eventually approved, Moderna said it plans to make at least 500,000 doses available to low- and middle-income countries at access pricing under its agreement with CEPI. Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda.

CityNews Calgary
Aug 4th, 2026
Health Canada authorizes Moderna clinical trial for new Ebola vaccine candidate.

Health Canada authorizes Moderna clinical trial for new Ebola vaccine candidate. By Nicole Ireland, The Canadian Press Posted Aug 4, 2026 11:41 am. Health Canada has authorized Moderna to conduct a clinical trial on a new mRNA vaccine that targets the form of Ebola blamed for the largest outbreak ever reported in the Democratic Republic of Congo. There is no vaccine or treatment for the Bundibugyo type of Ebola, which has killed more than 1,700 people in Congo. Ebola has never been detected in Canada but it will be the first country to participate in Moderna's trial in a global race to develop a vaccine. Participants are healthy adults and will not be exposed to the virus to test the vaccine. A spokesperson for Moderna says the first volunteer in the trial received the shot on Monday in Truro, N.S., and that the company expects to enrol 80 people in Truro, Halifax and Toronto. The Phase 1 trial will evaluate the vaccine's safety, determine the right dosage, monitor for side effects and study the antibody response. Health Canada said in a release issued Tuesday that the department authorized the clinical trial on July 30. The United Kingdom has also started a clinical trial for a Bundibugyo virus vaccine, made by the University of Oxford. Health Canada said Moderna would need to do Phase 2 and 3 clinical trials to determine the vaccine's effectiveness before it could seek authorization for wider use. "Any final submission would need to meet Health Canada's stringent safety, efficacy and quality standards before the vaccine could be allowed on the Canadian market," the department's news release said. Ebola is spread through unprotected contact with the bodily fluids of people sick with the virus or who have died from it. Ebola is a filovirus, which can cause severe hemorrhagic fever. Moderna's executive director of global health security and R&D partnerships said Canada was chosen for the first clinical trial "based on Moderna's experience conducting early-phase trials there, Health Canada's regulatory oversight, and the country's long-standing contributions to filovirus research." "Canadian researchers and participants are contributing an important first step in a broader international effort to develop a vaccine against a form of Ebola for which no approved protection is currently available," Hamilton Bennett said in an emailed statement. The Bundibugyo form of Ebola was first declared an outbreak on May 15 and has spread in Congo and neighbouring Uganda. The World Health Organization has deemed it a public health emergency of international concern. With files from The Associated Press Keep it Factual Add CityNews Calgary as a trusted source on Google to see more local stories from us.

The Seattle Times
Aug 4th, 2026
Moderna begins human trial of experimental Ebola vaccine in Canada.

Moderna begins human trial of experimental Ebola vaccine in Canada. Aug. 4, 2026 at 9:29 am Moderna Inc. has begun testing an experimental Ebola vaccine in people, marking the second candidate to enter clinical trials against the strain driving the deadliest Ebola outbreak in Democratic Republic of Congo's history. The vaccine, which uses the company's mRNA platform, is being tested as a single shot in about 80 healthy adults in Canada. Initial safety and immune-response data are expected in the coming months, Moderna said Tuesday. The program is backed by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million to fund the phase-1 trial and manufacture additional vaccine doses in parallel so larger studies can begin quickly if the early data are encouraging. CEPI is accelerating efforts to develop vaccines against the rare Bundibugyo strain as the outbreak continues to worsen. It spread to a fifth Congolese province last month, while the confirmed death toll has doubled in just over two weeks to 1,707. As of Sunday, authorities had reported 3,802 confirmed cases, making it the largest since the 2013-16 West Africa outbreak. "Getting Moderna's vaccine candidate into a phase-1 trial this rapidly is a major step forward in the fight against this deadly outbreak," CEPI's Chief Executive Officer Richard Hatchett said in a statement. If licensed, Moderna said it would make at least 500,000 doses available to low- and middle-income countries under access pricing. Advertising There are no approved vaccines or therapies for Bundibugyo Ebola. Merck & Co.'s Ervebo vaccine, which is licensed against the Zaire strain responsible for Congo's previous major outbreak and the West Africa epidemic, isn't approved for Bundibugyo. Still, the Africa Centres for Disease Control and Prevention and its partners plan to present a proposal to a World Health Organization advisory panel this week to consider using the vaccine to help protect frontline health workers, at least 46 of whom have died in the outbreak. Moderna's vaccine joins an adenovirus-vectored candidate developed by the University of Oxford that entered phase-1 testing last month, while Merck and its partners are preparing a third Bundibugyo vaccine based on the technology behind Ervebo for human studies later this year. - With assistance from Robert Langreth. (C) 2026 Bloomberg L.P. This story was originally published at bloomberg.com. Read it here. See more Seattle Times content on Google The Seattle Times does not append comment threads to stories from wire services such as the Associated Press, The New York Times, The Washington Post or Bloomberg News. Rather, Seattle Cricket focus on discussions related to local stories by its own staff. You can read more about its community policies here.

Darpan Magazine
Aug 4th, 2026
Two planes crash in mid-air near Chilliwack airport, officials say.

Two planes crash in mid-air near Chilliwack airport, officials say. Darpan News Desk The Canadian Press, 04 Aug, 2026 11:05 AM Two planes from a pair of flight schools crashed Monday while flying near the city of Chilliwack in British Columbia's Fraser Valley. Garry Atkins with the Chilliwack Airport says one of the aircraft carrying two occupants safely landed at the airport. He says the second plane became submerged in a quarry lagoon and that one person was reported to be on board. BC Emergency Health Services says five ambulances were dispatched to an area of Wolfe Road and Schweyey Road, northwest of the airport, and that no patients were taken to hospital. RCMP did not immediately respond to a request for comment. Chilliwack is about 100 kilometres east of Vancouver. Picture Courtesy: THE CANADIAN PRESS/Adrian Wyld MORE National ARTICLES. Growing up on a cattle farm in eastern Alberta, Joshua Kutryk says he dreamt of going to space though he never thought it would happen. The chief of the Okanagan Indian Band says about 230 homes have been destroyed by a raging wildfire near Vernon, B.C. Health Canada has authorized Moderna to conduct a clinical trial on a new mRNA vaccine that targets the form of Ebola blamed for the largest outbreak ever reported in the Democratic Republic of Congo. An animal-rights activist from Saskatchewan is among those detained off the coast of Reykjavik, Iceland's capital, on a ship operated by a group founded by anti-whaling activist Paul Watson. Residents in Metro Vancouver are waking up to an orange, hazy sky partially obscuring the sun as smoke from wildfires in the British Columbia Interior spreads across the province. A Metro Vancouver man has been charged following a multi-year investigation into alleged sexual exploitation of a youth more than two decades ago. * 1 * 2 * 3 * 4

Yahoo Finance
Jul 31st, 2026
Moderna narrows Q2 loss to $782M, beats estimates as norovirus vaccine trial fails interim analysis

Moderna reported a second-quarter net loss of $782 million, or $1.97 per share, beating analyst estimates of a $2.03 loss. However, shares fell 5.7% in premarket trading after the company announced its norovirus vaccine candidate failed to meet statistical criteria for early success at a Phase 3 interim analysis. Total revenue rose slightly to $145 million from $142 million year-over-year, driven by UK government partnership deliveries that offset lower COVID-19 vaccine sales. Operating expenses declined across categories, with research and development costs dropping 7% to $651 million. Moderna improved its 2026 outlook, lowering expected cost of sales to approximately $1.7 billion and raising projected year-end cash balance to $4.7 billion to $5.2 billion. The company holds $6.9 billion in cash and investments. Moderna awaits FDA decision on its seasonal influenza vaccine by 5 August, which would become its fifth approved product.